Search - tctmd.com

Displaying 1 - 20 of 108

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Advertisement

Year in Review: Top Prevention Stories of 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content